Outset Medical, Inc. · NASDAQ:OM
Outset Medical — 45th Annual TD Cowen Health Care Conference (March 2025)
25 slides from Outset Medical's conference presentation, Mar 4, 2025
Slide 1: Outset Medical at 45th Annual TD Cowen Health Care Conference
Leslie Trigg, Chair & CEO Outset Medical 45th Annual TD Cowen Health Care Conference March 4, 2025
Slide 2: Forward-looking statements and non-GAAP information
Forward-looking statements and non-GAAP information This presentation and the accompanying oral statements contain which could cause actual results to differ materially from those undertake no obligation to publicly update or revise any forward- forward-looking statements within the meaning of the f
Slide 3: Catalyzing profound and permanent change in where, when and how dialysis is delivered
Catalyzing profound and permanent change in where, when and how dialysis is delivered. 3 Outset Medical, Inc. - Confidential & Proprietary - Do Not Distribute
Slide 4: Investment Highlights
Investment Highlights Large markets Growing footprint Recurring Commercial Capitalized served by a and scale with revenue model transformation through technology with hundreds of powered by focused on breakeven and deep and durable customers and predictable reigniting well-positioned to competitive
Slide 5: Dialysis is one of the largest, most expensive, least-changed sectors of healthcare
CURRENT STATE Dialysis is one of the largest, most expensive, least-changed sectors of healthcare 2022 2030 $73B Annual spending on 1 $41B 1 7% 2 for 1% 2 30% 3 Paid by Medicare U.S. ESRD patients 600,000 3 Dialysis patients 90M 3 Annual dialysis treatments 1. Company estimates based on data contain
Slide 6: Patient Journey Spans Hospital to Home
Patient Journey Spans Hospital to Home CKD/ESRD PATIENTS POST ACUTE ACUTE FACILITIES 60% CRASH INTO DIALYSIS HOME 600,000 Total U.S. dialysis patients MID-SIZED DIALYSIS OPERATORS 40% MANAGED INTO DIALYSIS Note: “CKD” represents Chronic Kidney Disease; “ESRD” represents End Stage Renal Disease Compa
Slide 7: Dialysis needs new solutions
CURRENT STATE Dialysis needs new solutions Costly Complicated Antiquated 7 Outset Medical, Inc. - Confidential & Proprietary - Do Not Distribute
Slide 8: We see a technology-driven way forward
We see a technology-driven way forward
Slide 9: Tablo is a first-of-its-kind technology designed to reduce the cost and complexity of dialysis
Tablo is a first-of-its- ® kind technology designed to reduce the cost and complexity of dialysis Single device Connected and Small and from ICU to home intelligent mobile
Slide 10: One device, multiple markets
One device, multiple markets $11.4B $2.5B $8.9B U.S. TAM Acute and Post-Acute Market Home market Company estimates based on data contained in USRDS 2021 Annual Data Report
Slide 11: One device, multiple markets
One device, multiple markets $11.4B $2.5B $8.9B U.S. TAM Acute and Post-Acute Market Home market Company estimates based on data contained in USRDS 2021 Annual Data Report
Slide 12: Dialysis is a Cost Center for Hospitals
Dialysis is a Cost Center for Hospitals Hospitals must cover the costs of delivering dialysis without reimbursement. Majority of hospitals outsource dialysis ~$1,200-$1,500 per treatment in the ICU ~$450-$550 per treatment for dialysis on the floor ~60% of hospitals stays involving dialysi
Slide 13: Tablo Reduces the Cost of Acute Dialysis
Tablo Reduces the Cost of Tablo Cost Per Treatment Acute Dialysis ~$300 Total Potential Cost Savings 50% – 80% Potential payback period <1 year Before Tablo With Tablo Supplies Existing ICU machines require Tablo creates the dialysate on demand, numerous dialysate bags for each eliminating the cost
Slide 14: Customer testimonials
Customer testimonials 2 $450K 40-65% 1 4.8 days Net savings projected in first year Savings in daily cost per tx Reduction in ICU mean length of stay $550 $1.5M $1M Net savings estimated per treatment Estimated annual supply savings Reduction in total ICU dialysis tx costs 94% $1.4M $50 Net savings
Slide 15: Scale of Tablo in the Acute Care setting
ACUTE CARE Scale of Tablo in the Acute Care setting 10 of 10 8 of 8 850 LARGEST SUBACUTE PROVIDERS TOP NATIONAL HEALTH SYSTEMS UNIQUE ACUTE SITES >1 million treatments >10,000 nurses and Extensive clinical evidence: annually 1,000 physicians 70+ abstracts trained 15+ manuscripts
Slide 16: One device, multiple markets
One device, multiple markets $11.4B $2.5B $8.9B U.S. TAM Acute and Post-Acute Market Home market Company estimates based on data contained in USRDS 2021 Annual Data Report
Slide 17: The Home market is significantly underpenetrated
HOME CARE The Home market is significantly underpenetrated Historical barriers REIMBURSEMENT EDUCATION TECHNOLOGY Medicare reimbursement Patient and physician Cumbersome technology and misaligned with treatment awareness low training frequency
Slide 18: Tablo addresses key barriers to home dialysis adoption and retention
HOME CARE Tablo addresses key barriers to home dialysis adoption and retention Historical device 3 5–6 Treatments per week Treatments per week <25 hours1 100 hours Training per patient Training per patient 0 hours 16–24 hours Dialysate prep time Dialysate prep time per week 1 Hemodialysis Internatio
Slide 19: Home growth strategy
Home growth strategy $8.9B TAM MDOs Mid-Sized Dialysis Organizations 180K patients Home
Slide 20: Home growth strategy
Home growth strategy NEW HOME DIALYSIS MARKET ENTRANTS IMMEDIATE TERM Skilled nursing facilities & other post-acute providers Health systems NEAR TERM 30% $8.9B MDOs of the market1 TAM 1. Outset estimates the $8.9 billion total addressable market for Tablo’s use in the home represents revenue from 3
Slide 21: Commercial Strategy Overview
Commercial Strategy Overview Key Value Drivers Cost savings Acute-care hospitals Improved clinical care and efficiency ACUTE Cost savings Long-term acute care (LTAC) & Rehab Facilities New patient referral source; incremental revenue New revenue stream Skilled Nursing Facilities (SNF) Tr
Slide 22: Powerful recurring revenue of >60% and expected to grow over time
Powerful recurring revenue of >60% Growth potential and expected to grow over time ACUTE FUTURE Software $20,000 per console EMR interoperability per year HOME $15,000 per console TODAY per year Consumables Service contracts
Slide 23: Entering 2025 capitalized through cashflow breakeven
Entering 2025 capitalized through cashflow breakeven1 $169M $100M +5 years $210M Gross proceeds Reduced debt on Maturity on new Estimated Cash from Jan 2025 balance sheet debt facility Position equity financing entering 20252 Led by marquee investors 1 Company expectation based on current projection
Slide 24: ‘Outset Medical, Inc. ‘Outset Media, ne
‘Outset Medical, Inc. ‘Outset Media, ne ‘Outset Medica, ns i fedical, inc set pares 4 ok) ‘use he noe sa eat Nato Pree! Cater Doing alysis at home can give people ther lives — and their ck Just ask atonal Pane Asanens er ped Tablo — a fstof-ts-knd te Dick & Lz. When Diek’s peritoneal dialysis was na
Slide 25: Outset Medical contact
Outset Medical 3052 Orchard Drive San Jose, CA 95134 outsetmedical.com For Important safety information, please refer to: https://www.outsetmedical.com/indications/
Outset Medical — 45th Annual TD Cowen Health Care Conference (March 2025) on 6ix